The angiotensin-(1-7) receptor agonist AVE0991 dominates the circadian rhythm and baroreflex in spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 2, 2007, Pages 67-73

  Wessel, N ^a   Malberg, H ^b   Heringer Walther, S ^c,d   Schultheiss, H P ^c   Walther, T ^c,d  

^a UNIVERSITY OF POTSDAM   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin (1 7); Baroreceptor sensitivity; Blood pressure variability; Heart rate; Radiotelemetry; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR STIMULATING AGENT; ANGIOTENSIN[1-7]; ANTIHYPERTENSIVE AGENT; AVE 0991; HORMONE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; AUTONOMIC INNERVATION; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR FUNCTION; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; HEART RATE VARIABILITY; MALE; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TREATMENT DURATION;

ANGIOTENSIN I; ANIMALS; BAROREFLEX; BLOOD PRESSURE; CIRCADIAN RHYTHM; HEART RATE; IMIDAZOLES; MALE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33847200132     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31802cffe9     Document Type: Article

References (47)

1. Kleiger RE, Miller JP, Bigger JT, et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987;59:256-262.
2. Tsuji H, Larson MG, Venditti FJ, et al. Impact of reduced heart rate variability on risk for cardiac events. Circulation. 1996;94:2850-2855.
3. Hofmann J, Grimm W, Menz V, et al. Heart rate variability and baroreflex sensitivity in idiopathic dilated cardiomyopathy. Heart. 2000;83:531-538.
4. Szabo BM, van Veldhuisen DJ, van der Veer N, et al. Prognostic value of heart rate variability in chronic congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol. 1997;79:978-980.
5. Ferrario CM. Angiotensin I, angiotensin II and their biologically active peptides. J Hypertens. 2002;20:805-807.
6. Loot AE, Roks A, Henning RH, et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548-1550.
7. Santos RAS, Simões e Silva AC, Magaldi AJ, et al. Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension. 1996;27:875-884.
8. Li P, Chappell MC, Ferrario CM, et al. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29:394-400.
9. Campagnole-Santos MJ, Diz DI, Santos RAS, et al. Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Physiol. 1989;257:H324-H29.
10. Chaves GZ, Caligiorne SM, Santos RAS, et al. Evidence that endogenous angiotensin-(1-7) participates in the modulation of the baroreflex at the nucleus tractus solitarii. Hypertension. 1995;25:1389.
11. Silva LCS, Fontes MAP, Campagnole-Santos MJ, et al. Cardiovascular effects produced by microinjection of angiotensin-(1-7) on vasopressor and vasodepressor sites of the ventrolateral medulla. Brain Res. 1993;613:321-325.
12. Fontes MAP, Silva LCS, Campagnole-Santos MJ, et al. Evidence that angiotensin-(1-7) plays a role in the central control of blood pressure at the ventrolateral medulla acting through specific receptors. Brain Res. 1994;665:175-180.
13. Campagnole-Santos MJ, Heringer SB, Batista EN, et al. Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am J Physiol. 1992;263:R89-R94.
14. Kohara K, Brosnihan KB, Ferrario CM. Angiotensin(1-7) in the spontaneously hypertensive rat. Peptides. 1993;14:883-891.
15. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994;23:439-449.
16. Chappell MC, Piro NT, Sykes A, et al. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension. 1998;31:362-367.
17. Heringer-Walther S, Batista EN, Santos RAS, et al. Baroreflex improvement in SHR after ACE inhibition by angiotensin-(1-7). Hypertension. 2001;37:1309-1314.
18. Santos RAS, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogeneous ligand for the G protein-coupled receptor Mas. Proc Nat Acad Sci USA. 2003;100:8258-8263.
19. Young, D, Waitches G, Birchmeier C, et al. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell. 1986;45:711-719.
20. Bunnemann B, Fuxe K, Metzger R, et al. Autoradiographic localization of mas proto-oncogene mRNA in adult rat brain using in situ hybridization. Neurosci Lett. 1990;114:147-153.
21. Metzger R, Bader M, Ludwig T, et al. Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett. 1995;357:27-32.
22. Villar AJ, Pedersen RA. Parental imprinting of the Mas protooncogene in mouse. Nat Genet. 1994;8:373-379.
23. Walther T, Balschun D, Voigt JP, et al. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem. 1998;273:11867-11873.
24. Walther T, Wessel N, Kang N, et al. Altered heart rate and blood pressure variability in mice lacking the Mas protooncogene. J Clin Bas Cardiol. 1999;2:281-282.
25. Walther T, Voigt JP, Fink H, et al. Sex specific behavioural alterations in Mas-deficient mice. Behav Brain Res. 2000;107:105-109.
26. Wiemer G, Dobrucki LW, Louka FR, et al. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension. 2002;40:847-852.
27. Kurths J, Voss A, Witt A, et al. Quantitative analysis of heart rate variability. Chaos. 1995;5:88-94.
28. Voss A, Kurths J, Kleiner HJ, et al. The application of methods of nonlinear dynamics for the improved and predictive recognition of patients threatened by sudden cardiac death. Cardiovasc Res. 1996;31:419-433.
29. Malberg H, Wessel N, Schirdewan A, et al. Duale Sequenzmethode zur Analyse der spontanen Baroreflexsensitivität bei Patienten mit dilatativer Kardiomyopathie. Z Kardiol. 1999;88:331-337.
30. Wessel N, Ziehmann Ch, Kurths J, et al. Short-term forecasting of lifethreatening cardiac arrhythmias based on symbolic dynamics and finitetime growth rates. Phys Rev E. 2000;61:733-739.
31. Malberg H, Wessel N, Hasart A, et al. Advanced analysis of the spontaneous baroreflex sensitivity, blood pressure and heart rate variability in patients with dilated cardiomyopathy, Clin Sci. 2002;102:465-473.
32. Wessel N, Schirdewan A, Kurths J. Intermittently decreased beat-to-beat variability in congestive heart failure. Phys Rev Lett. 2003;91:119801.
33. Wessel N, Voss A, Malberg H, et al. Nonlinear analysis of complex phenomena in cardiological data. Herzschr Elektrophys. 2000;11:159-173.
34. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93:1043-1065.
35. Parlow J, Viale JP, Annat G, et al. Spontaneous cardiac baroreflex in humans. Hypertension. 1995;25:1058-1068.
36. Berntson GG, Bigger JT, Eckberg DL, et al. Heart rate variability: origins, methods, and interpretative caveats. Psychophysiology. 1997;34:623-648.
37. Meyerfeldt U, Wessel N, Schütt H, et al. Heart rate variability before the onset of ventricular tachycardia: Differences between slow and fast arrhythmias. Int J Cardiol. 2002;84:141-151.
38. Shan ZZ, Dai SM, Su DF. Relationship between baroreceptor reflex function and end-organ damage in spontaneously hypertensive rats. Am J Physiol. 1999;277:H1200-206.
39. Miao CY, Shen FM, Su DF. Blood pressure variability is increased in genetic hypertension and L-NAME -induced hypertension. Acta Pharmacol Sin. 2001;22:137-140.
40. Baltatu O, Janssen BJ, Bricca G, et al. Alterations in blood pressure and heart rate variability in transgenic rats with low brain angiotensinogen. Hypertension. 2001;37:408-413.
41. da Silva Lemos M, Nardoni Goncalves Braga A, Roberto da Silva J, et al. Altered cardiovascular responses to chronic angiotensin II infusion in aged rats. Regul Pept. 2005;132:67-73.
42. Braga AN, da Silva Lemos M, da Silva JR, et al. Effects of angiotensins on day-night fluctuations and stress-induced changes in blood pressure. Am J Physiol Regul Integr Comp Physio. 2002;282:R1663-671.
43. Oosting J, Struijker-Boudier HA, Janssen BJ. Autonomic control of ultradian and circadian rhythms of blood pressure, heart rate, and baroreflex sensitivity in spontaneously hypertensive rats. J Hypertens. 1997;15:401-410.
44. Kuo TB, Yang CC. Sleep-related changes in cardiovascular neural regulation in spontaneously hypertensive rats. Circulation. 2005;112:849-854.
45. Chan SH, Chao YM, Tseng CJ, et al. Down-regulation of basal Fos expression at nucleus tractus solitarii underlies restoration of baroreflex response after antihypertensive treatment in spontaneously hypertensive rats. Neuroscience. 2002;112:113-120.
46. Chaves GZ, Caligiorne SM, Santos RA, et al. Modulation of the baroreflex control of heart rate by angiotensin-(1-7) at the nucleus tractus solitarii of normotensive and spontaneously hypertensive rats. J Hypertens. 2000;18:1841-1848.
47. Langeveld B, van Gilst WH, Tio RA, et al. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension. 2005;45:138-141.